Related Experiment Videos
Transcatheter closure of atrial septal defect using buttoned device--Indian experience
R Arora1, V K Trehan, G S Kalra
1Department of Cardiology, GB Pant Hospital, New Delhi.
Indian Heart Journal
|March 1, 1996
Summary
Transcatheter closure of atrial septal defects (ASD) using the Sideris device is safe and effective for select patients. While successful in most cases, challenges like device slippage and mitral regurgitation were noted.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pediatric Cardiology
Background:
- Secundum atrial septal defects (ASD) are common congenital heart abnormalities.
- Transcatheter closure offers a minimally invasive alternative to surgical repair.
- Accurate device selection and implantation are crucial for successful outcomes.
Purpose of the Study:
- To evaluate the safety and efficacy of the Sideris buttoned device for transcatheter closure of secundum ASD.
- To assess the accuracy of transthoracic echocardiography (TTE) in measuring ASD diameter compared to balloon sizing.
- To report procedural success rates, shunt status, and long-term device stability.
Main Methods:
- Transcatheter closure was attempted in 27 patients (age 5-35 years) with ASD < 21 mm using the Sideris device.
- Fluoroscopic and TTE guidance were employed throughout the procedure.
- ASD diameter was assessed by TTE and balloon sizing during cardiac catheterization.
Main Results:
- Successful device implantation was achieved in 24 patients (89%).
- Complete shunt closure was observed in 17 patients (63%) by TTE.
- Residual shunts were noted in 7 patients, with device stability in all patients on follow-up (14.5 months).
- Complications included device unbuttoning/slippage (3 patients) and new-onset mitral regurgitation (5 patients).
Conclusions:
- Transcatheter closure of selected secundum ASDs with the Sideris device is feasible and safe.
- The Sideris device may be less suitable for larger defects, potentially impacting mitral valve function.
- Centering devices might offer better outcomes for larger ASDs with reduced mitral valve interference.